ASP Isotopes Inc. (ASPI) stock intrinsic value fair value estimate & owner earnings analysis

ASP Isotopes is a development-stage company that is trying to build a business around enriched isotopes (for medicine, semiconductors and nuclear energy), and since January 2026 also around helium and liquefied natural gas in South Africa through its acquisition of Renergen. Today the revenue it actually earns comes from three small, low-margin activities: nuclear medicine doses in South Africa and the United States, construction services in Hong Kong through its 79%-owned listed subsidiary Skyline Builders (about $18.2 million of the $23.8 million 2025 revenue, only since August 2025), and, from 2026, early liquefied gas sales from Renergen's Virginia Gas Plant. It has not yet sold any enriched isotopes. Gross profit was only $3.4 million on $23.8 million of 2025 revenue. How we value it: we measure what the business earns for its owners after every real cost, including stock compensation, and add back interest to see what the business itself produces before its lenders. That figure has been negative every year: about -$0.35, -$0.50, -$0.41 and -$0.60 per share for 2022 to 2025, and in the first half of 2026, after Renergen was consolidated, cash burn roughly doubled (operating cash flow of -$41.1 million, stock compensation of $9.0 million and $10.2 million of capital spending in six months). Net loss of $159.8 million in 2025 was mostly a $123.7 million non-cash increase in the value of convertible notes issued by its Quantum Leap Energy subsidiary, which reconciles to operating cash flow of -$37.8 million. Nothing in the filings puts positive owner earnings in hand: there is no signed enriched-isotope supply contract producing revenue, the Renergen helium plant is only starting to reach full output (wells are drilled but gas tie-ins are still in progress), and the $1.16 billion Phase 2 expansion depends on debt facilities that are only conditionally approved. Under our rules, growth that depends on things that have not yet happened is not counted, so those prospects are worth nothing in any of our cases. We also did not credit revenue growth from the Skyline acquisition beyond what is already in the run rate. What the company owes: at June 30, 2026 it held $219.6 million of cash and $35.3 million of short-term investments ($254.9 million). Against that sit $59.8 million of borrowings (mostly Renergen's South African development and industrial-bank loans, which carry financial covenants that start to apply 18 months after the plant is completed), about $199 million of convertible notes issued by Quantum Leap Energy (carried at fair value, maturing November 2030 or converting into that subsidiary's shares if it lists), small finance leases, and $10.1 million belonging to minority owners of subsidiaries. On balance the company's cash roughly matches what it owes: net obligations are about $15 million, or about $0.12 per share on roughly 122.7 million diluted shares. The three cases each run the current cost base (about $96 million a year of cash consumed by the business after stock compensation, before interest) only as long as the story can be defended. In the bull case, the Renergen plant reaching full output and the completed capital projects let spending stop after about one year: the business is worth about -$91 million (-$0.74 per share), it owes a net $15 million (-$0.12), so the shares are worth about -$0.86. In the base case the spending continues for about two years, roughly the runway the cash provides, before there is nothing left that is evidenced to sustain it: business worth about -$177 million (-$1.44 per share), owing $15 million net, so about -$1.56 per share. In the bear case the spending continues for about three years, funded by more borrowing or share sales, while Renergen's lender covenants and the 2030 convertible notes close in: business worth about -$258 million (-$2.10), owing $15 million net, so about -$2.22 per share. All three cases come out below zero, meaning that on evidence in hand the company appears to owe more than its earning power is worth, by roughly $0.9 to $2.2 per share. Because a share's value to its holder is limited to zero, this means any positive value for the shares rests only on undemonstrated future results, not that the shares can go below zero. What would make this wrong: signed multi-year helium or liquefied natural gas sales at the Virginia Gas Plant, Skyline or the medical business turning a consistent operating profit, a signed supply contract for enriched isotopes or nuclear fuel, or finalized debt funding for Phase 2 would each put real, evidenced cash flow into the valuation. The company also raised about $320 million of equity in 2025 and has consistently funded itself that way, so dilution is likely to continue. Two items we could not resolve from the filings: the exact June 30, 2026 balance of the convertible notes (we used the year-end fair value of $199.3 million), and separately-reported quarterly working capital movements, which we left out of the run-rate as immaterial. Approximately 76% of 2025 revenue was booked in Hong Kong through the Skyline construction business; the parent company is incorporated in Delaware and the enrichment and gas assets are in South Africa and the United States.